Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma 1Intermittent Fasting 1Fasting 1

Interventions

Lenalidomide 2Cyclophosphamide 2ibrutinib 1fludarabine 1Vincristine 1Ropivacaine 1Rituximab 1R-CHOP protocol 1Prednisone 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Maintenance 1Magnetic Resonance Spectroscopy 1Leukapheresis 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Etoposide 1Educational Status 1Doxorubicin 1Decitabine 1Brentuximab Vedotin 1Blood Specimen Collection 1Biopsy, Fine-Needle 1Bendamustine Hydrochloride 1Angptl4 protein, mouse 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Angptl4 protein, mouse × Lymphoid × Clear all
NCT06645093 2026-03-10

FasteStudien

University of Oslo

Phase NA Enrolling by invitation
40 enrolled
Lymphoid

Intermittent Fasting, Fasting, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡